Here's Why Retaining Cigna Stock is a Smart Move for Investors Now [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
A solid 2024 guidance acts as an additional tailwind for the company. Cigna carries a Zacks Rank #3 (Hold) at present. The stock has gained 17.1% in the past year compared with the industry's 6.9% growth. Image Source: Zacks Investment Research CI is well-poised for progress, as evidenced by its impressive VGM Score of B. Here V stands for Value, G for Growth and M for Momentum, and the score is a weighted combination of all three factors. The Zacks Consensus Estimate for CI's 2024 earnings is pegged at $28.50 per share, indicating an improvement of 13.6% from the year-earlier reading. The estimate for revenues is $243.8 billion, implying a 24.8% increase from the prior-year actual. The consensus mark for 2025 earnings is pegged at $31.59 per share, indicating 10.9% growth from the 2024 estimate. The estimate for revenues is $249.8 billion, which indicates a rise of 2.5% from the 2024 estimate. Cigna's earnings outpaced estimates in each of the trailing four quarters, th
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? [Yahoo! Finance]Yahoo! Finance
- Gastroparesis Drugs Market size to increase by USD 1.42 Billion between 2023 to 2028, Market Segmentation by Drug Class, Disease Type, Geography, Technavio [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $80.00 price target on the stock.MarketBeat
- Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? [Yahoo! Finance]Yahoo! Finance
ANIP
Earnings
- 11/8/24 - Beat
ANIP
Sec Filings
- 12/18/24 - Form 4
- 12/17/24 - Form 144
- 12/16/24 - Form 4
- ANIP's page on the SEC website